Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis

Digestive Diseases and Sciences

Volumn 60, Issue 1, 2015, Pages 9-12

  Wong, Grace Lai Hung ^a   Wong, Vincent Wai Sun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED ATTENUATION PARAMETER; DIAGNOSTIC ACCURACY; ECHOGRAPHY; EDITORIAL; ELASTOGRAPH; ELASTOGRAPHY; FATTY LIVER; HEPATOBILIARY PARAMETERS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER STIFFNESS; MEASUREMENT; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RADIATION ATTENUATION; RADIOLOGICAL PARAMETERS; FEMALE; HEPATITIS B; LIVER TRANSPLANTATION; LIVING DONOR; MALE; PROCEDURES;

ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; MALE;

EID: 84922076895     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3429-3     Document Type: Editorial

References (23)

1. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61:409–415.
2. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–974.
3. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253.
4. Chan HL, de Silva HJ, Leung NW, et al. How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol. 2007;22:801–808.
5. Clouston AD, Jonsson JR, Powell EE. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis. 2007;11:173–189, x.
6. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750.
7. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454–462.
8. Wong GL. Transient elastography: kill two birds with one stone? World J Hepatol. 2013;5:264–274.
9. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–1835.
10. de Ledinghen V, Vergniol J, Foucher J, et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–918.
11. Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–910.
12. Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R)): validation in chronic hepatitis C. J Viral Hepat. 2012;19:244–253.
13. Cardoso AC, Sasso M, Miette V, et al. Controlled attenuation parameter: a novel FibroScan-based tool to detect and quantify steatosis in chronic hepatitis B. http://onlinelibrary.wiley.com.easyaccess1.lib.cuhk.edu.hk/doi/10.1002/hep.23974/pdf.
14. Beaugrand M, de Ledinghen V, Douvin C, et al. Validation of controlled attenuation parameter (CAP) as a non-invasive marker of steatosis in 228 patients with chronic liver disease from various causes. J Hepatol. 2010;52:S35–S36.
15. ®-based tool to detect and quantify steatosis. Preliminary study in patient with alcoholoc and non alcoholic fatty liver disease. J Hepatol. 2010;52:S158–S159.
16. Chon YE, Jung KS, Kim KJ, et al. Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-014-3293-1.
17. ®): validation in chronic hepatitis B. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-014-3341-x.
18. Wong GL, Wong VW, Choi PC, et al. Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2009;24:1002–1007.
19. Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2009;16:36–44.
20. Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533–540.
21. Wong GL, Chan HL, Yu Z, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther. 2014;39:883–893.
22. Wong GL, Wong VW, Choi PC, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009;58:111–117.
23. Wong GL, Chan HL, Wong CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339–345.